Related Experiment Videos
IBC's conference on antibody engineering; new technology, application and commercialisation
J Wilton1, P Braddock, S Smith
1Cambridge Antibody Technology Ltd., The Science Park, Melbourn, Cambridgeshire, SG8 6JJ, UK.
Expert Opinion on Investigational Drugs
|July 5, 2005
Summary
Antibody engineering advances, including larger libraries and novel selection methods, are improving therapeutic antibody development. Early clinical data for engineered antibodies show promise for treating diseases with unmet needs.
Area of Science:
- Biotechnology
- Immunology
- Drug Discovery
Background:
- The first European antibody engineering conference convened to discuss progress in the field.
- This meeting served as the European counterpart to the established US annual conference.
Purpose of the Study:
- To provide an update on the latest advancements in all facets of antibody engineering.
- To highlight key developments in antibody library design, selection techniques, and clinical applications.
Main Methods:
- Review of recent progress in antibody library design and diversity.
- Discussion of novel selection technologies, including phenotypic selections and ribosome display.
- Analysis of clinical trial data for engineered antibodies.
Main Results:
- Significant increases in antibody library size and diversity were reported.
- Novel selection technologies enhance accessibility to new therapeutic targets.
- Engineered antibodies in clinical trials show promising results, offering improved therapies or novel treatments.
Conclusions:
- Antibody engineering is rapidly advancing with improved library and selection technologies.
- Engineered antibodies represent a promising therapeutic modality for various diseases.
- Clinical data suggest significant potential for antibody-based treatments in areas with unmet medical needs.